HAVN Life Signs Exclusive Supply Agreement With Cube Psytech
Havn Life Sciences (CSE:HAVN, OTC PINK:HAVLF) has announced a new supply agreement with Cube Psytech, a biopharmaceutical firm focused on psilocybin microdosing health products. The collaboration will leverage Havn Life's mushroom cultivation operations in Jamaica and supports Cube Psytech's development of products compliant with Health Canada guidelines. CEO Tim Moore emphasized their commitment to meeting the growing demand for naturally-derived psilocybin, while Cube Psytech's CEO expressed confidence in Havn Life as a reliable supplier.
- New supply agreement with Cube Psytech enhances business opportunities.
- Utilizes Havn Life's established mushroom cultivation operations in Jamaica.
- Supports the growing demand for naturally-derived psilocybin products.
- None.
The Company will supply naturally-derived psilocybin for the development of psilocybin microdosing health products
VANCOUVER, BC / ACCESSWIRE / July 8, 2021 / Havn Life Sciences Inc. (CSE:HAVN) (OTC PINK:HAVLF) (FSE:5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is announcing a new supply agreement with Cube Psytech, a biopharmaceutical and biotechnology company focused on sustainable, natural medicine that is developing a proprietary line of psilocybin microdosing health products with functional and psychedelic mushrooms.
Based in Vancouver, Cube Psytech is currently raising funds for the construction and development of a Health Canada approved CGMP facility, as well as a research and development lab for product development. This agreement with Cube Psytech further adds to HAVN Life's growing list of supply partners, leveraging the Company's mushroom cultivation and production operations in Jamaica as a robust revenue stream.
"We are very happy to add Cube Psytech to our list of supply partners," says HAVN Life CEO, Tim Moore. "We've been working tirelessly to build out a full-fledged supply chain out of our facility in Jamaica as we continue to see demand for naturally derived psilocybin products. We are ready and willing to meet this demand," he adds.
"We're excited to build this relationship with HAVN Life," says Cube Psytech CEO and Co-Founder Erick Factor. "We have been looking to secure a safe and standardized supply of psilocybin for the development of our products. We feel that HAVN Life is the ideal partner to fulfil this requirement," he adds.
The agreement and supply of psilocybin to Cube Psytech will be in compliance with Health Canada guidelines.
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer
About Havn Life Sciences Inc.
HAVN Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural health products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and YouTube.
Contact:
Investor Relations: ir@havnlife.com 604 687-7130
Media: savi@emergence-creative.com 647 896-8078
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release
SOURCE: Havn Life Sciences Inc.
View source version on accesswire.com:
https://www.accesswire.com/654595/HAVN-Life-Signs-Exclusive-Supply-Agreement-With-Cube-Psytech
FAQ
What is the recent partnership between Havn Life Sciences and Cube Psytech about?
What products will Havn Life supply to Cube Psytech?
Is the supply of psilocybin from Havn Life compliant with regulations?
What does the new supply agreement mean for Havn Life's business?
When was the supply agreement between Havn Life and Cube Psytech announced?
